Briliumvi (sample new)

Drug Overview

In the rapidly evolving field of Neurology, managing multiple sclerosis (MS) requires highly efficient and convenient treatment options to protect the central nervous system from long-term damage. Briliumvi (sample new) is an innovative medication belonging to the CD20-Directed Cytolytic Antibodies drug class. It represents a significant advancement in infusion treatments for patients with relapsing forms of MS.

Classified as a sophisticated, large-molecule Biologic, Briumvi functions as a highly precise Immunotherapy. Instead of broadly suppressing the entire immune system, it acts as a specific Targeted Therapy designed to identify and eliminate a particular type of white blood cell responsible for driving the autoimmune attack. By keeping these destructive cells depleted, it effectively reduces MS relapses and slows the accumulation of physical disability.

• Generic Name: Ublituximab (or ublituximab-xiiy)
• US Brand Names: Briumvi
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Fully FDA-approved for the treatment of relapsing forms of multiple sclerosis in adults (approved in the US and the EU).

What Is It and How Does It Work? (Mechanism of Action)

Briumvi is a unique, glycoengineered chimeric monoclonal antibody. In multiple sclerosis, the immune system incorrectly identifies the myelin sheath (the protective coating around nerve fibers) as a foreign threat. Recent science has proven that a specific type of white blood cell, the B-cell, plays a central role in coordinating this inflammatory attack on the brain and spinal cord.

At the molecular level, its mechanism of action utilizes advanced cellular engineering:

• Targeted Binding: Ublituximab is designed to seek out and bind exclusively to the CD20 protein. This specific marker is found only on the surface of pre-B and mature B lymphocytes.
• Glycoengineering (The “Afucosylated” Advantage): What makes Briumvi unique is how it is manufactured. It is “afucosylated,” meaning certain sugar molecules (fucose) have been removed from the antibody’s structure. This specific engineering dramatically enhances the drug’s binding affinity to the body’s natural killer (NK) cells.
• Cellular Destruction: Because of this enhanced binding, Briumvi triggers an incredibly potent immune response called Antibody-Dependent Cellular Cytotoxicity (ADCC). It rapidly and efficiently destroys the targeted CD20-positive B-cells at much lower doses than older medications in its class.
• Preserving Immunity: Importantly, the CD20 marker is absent on bone marrow stem cells (which create new immune cells) and plasma cells (which maintain antibodies from past vaccines and infections). This allows the body to retain its core immune memory while the aggressive MS-causing B-cells are cleared.

FDA-Approved Clinical Indications

Primary Indication

• Relapsing Forms of Multiple Sclerosis (MS): Briumvi is explicitly indicated for the treatment of adult patients with relapsing forms of multiple sclerosis. This includes:
  • Clinically Isolated Syndrome (CIS)
  • Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Active Secondary Progressive Disease (SPMS)

Other Approved Uses

Due to its highly specialized engineering to target B-cells involved in central nervous system inflammation, Briumvi has a highly focused clinical profile.

• There are currently no FDA-approved uses for Briumvi in oncology, cardiovascular medicine, nephrology, or general medicine.

Dosage and Administration Protocols

Thanks to its enhanced potency, Briumvi allows for significantly faster maintenance infusions compared to older therapies in its class.

Clinical Protocol Notes

• Premedication Requirement: To minimize infusion reactions, patients must receive premedication with an IV corticosteroid (like methylprednisolone) and an antihistamine (like diphenhydramine) approximately 30 to 60 minutes before every infusion.
• Hepatic and Renal Insufficiency: As a monoclonal antibody, ublituximab is degraded into smaller peptides and amino acids via standard catabolic pathways. No specific dosage adjustments are required for patients with mild to severe renal or hepatic impairment.

Clinical Efficacy and Research Results

Clinical trials (the ULTIMATE I and II studies) and subsequent real-world follow-up data from 2023 to 2026 position Briumvi as an exceptionally high-efficacy therapy:

• Relapse Rate Reduction: Clinical data demonstrate that patients treated with Briumvi experience extremely low annualized relapse rates (ARR of less than 0.10), representing a relative reduction of approximately 60% compared to oral therapies like teriflunomide.
• MRI Biomarker Improvement: Brain imaging confirms that Briumvi suppresses acute neuroinflammation almost completely. It reduces the number of active, gadolinium-enhancing T1 lesions by over 97% compared to active comparators.
• No Evidence of Disease Activity (NEDA): Extended research shows a high proportion of patients on Briumvi achieve NEDA—meaning they experience no relapses, no new MRI lesions, and no disability progression over multiple years of therapy.

Safety Profile and Side Effects

Briumvi does not carry a “Black Box Warning,” but its B-cell depleting nature requires strict monitoring for specific infusion-related and infectious risks.

Common Side Effects (>10%)

• Infusion Reactions: The most common side effect (up to 48% of patients), especially during the very first infusion. Symptoms include fever, chills, headache, throat irritation, and nausea.
• Upper respiratory tract infections (colds, sinus infections).
• Extremity pain and joint pain.

Serious Adverse Events

• Infectious: Increased risk of severe, potentially life-threatening infections, including herpes simplex and herpes zoster (shingles).
• Neurological (PML): While rare, Progressive Multifocal Leukoencephalopathy (PML)—an opportunistic viral infection of the brain that can cause severe disability or death—is a known risk for all CD20-depleting therapies.
• Hepatic: Reactivation of Hepatitis B Virus (HBV), which can lead to rapid, severe liver failure.
• Immunological: Decreased levels of protective immunoglobulins (hypogammaglobulinemia) over prolonged use, which may require monitoring if a patient experiences recurrent infections.

Management Strategies

• Managing Infusion Reactions: If a patient develops a reaction during the IV drip, the standard clinical protocol is to immediately slow, pause, or halt the infusion and administer additional symptom-relief medications. The rapid 1-hour maintenance infusions are generally very well tolerated after the initial doses.
• Infection Management: If an active, severe infection occurs, Briumvi infusions must be delayed until the infection is fully resolved.

Connection to Stem Cell and Regenerative Medicine

In the pioneering field of Regenerative Medicine for multiple sclerosis, CD20-targeted therapies like Briumvi are considered vital foundational tools. Current research (2025–2026) dictates that therapies aimed at rebuilding the myelin sheath (remyelination) or utilizing neural stem cells cannot succeed in an environment filled with aggressive, attacking B-cells. By utilizing this Immunotherapy to efficiently clear out the disease-causing cells in just one hour every six months, neurologists create a stable, non-inflammatory “permissive microenvironment.” Establishing this quiet neurochemical baseline is an essential prerequisite to ensure the survival, engraftment, and functional success of future cellular repair therapies in the brain and spinal cord.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Hepatitis B Screening: Absolute requirement to test for Hepatitis B surface antigen (HBsAg) and core antibody (anti-HBc) to rule out active or latent HBV infection.
• Serum Immunoglobulins: A baseline test of quantitative immune proteins (IgG and IgM) to monitor for drug-induced drops over the years.
• Pregnancy Testing: For females of reproductive potential, to ensure the patient is not pregnant before receiving the Biologic.
• Vaccination Review: All necessary “live” or “live-attenuated” vaccines must be administered at least 4 weeks before starting Briumvi. Non-live vaccines should be given at least 2 weeks prior.

Precautions During Treatment

• Vaccine Restrictions: Patients must avoid all live vaccines while on Briumvi and until B-cell counts have fully recovered.
• Symptom Vigilance: Patients must be alert to early signs of infection (fever, persistent cough, burning during urination) and immediately report any new, unusual neurological symptoms (such as sudden extreme clumsiness or confusion) that could indicate PML.

“Do’s and Don’ts” List

• DO hydrate well the day before your infusion to make IV placement easier and help your body process the medication.
• DO schedule your subsequent 1-hour maintenance infusions exactly every 24 weeks to prevent the MS-causing B-cells from returning.
• DON’T receive any immunizations without explicitly telling the pharmacist or doctor that you are on a B-cell depleting therapy.
• DON’T ignore symptoms of an allergic reaction during your IV drip, such as a scratchy throat, sudden hives, or shortness of breath; notify your infusion nurse immediately.

Legal Disclaimer

This guide is intended for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Multiple sclerosis is a highly complex, chronic neurological condition requiring precise medication management and ongoing supervision by a board-certified neurologist or MS specialist. Always consult your healthcare provider before initiating, altering, or stopping any medication regimen.